Alec Broers becomes chairman of Bio Nano Consulting
Brings extensive industry, academic and scientific expertise to company
Broers has extensive industry, academic and scientific expertise and was chairman of the House of Lords Science and Technology Select Committee between 2004 and 2007.
At Bio Nano Consulting he will facilitate ongoing partnerships between academia and the wider life science and technology industries.
Educated at Melbourne University and the University of Cambridge, Broers subsequently worked in r&d at IBM laboratories in the US for 19 years, ultimately taking responsibility for the company’s chip development.
Broers returned to the UK in 1984 as head of Electrical Engineering at Cambridge University and Fellow of Trinity College. He subsequently became head of the Department of Engineering and Master of Churchill College.
More recently, Broers was Vice Chancellor of Cambridge University and president of the Royal Academy of Engineering from 2001 to 2006. He was knighted in 1998 for services to education before being made a life peer in 2004.
Bio Nano Consulting is a joint venture of Imperial College London and University College London that specialises in solutions to industry across the life sciences and technology sectors.
You may also like
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development
Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery
The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform